Big Money Are Buying Medicinova Inc (NASDAQ:MNOV), Sentiment at 1.15

Positions for Medicinova Inc (NASDAQ:MNOV)

“Big money sentiment for Medicinova Inc (NASDAQ:MNOV) in Q3 2018 increased to 1.15, revealed SEC filings. That’s up 0.11, from 2018Q2’s 1.04. 23 institutional investors increased or started new holdings, while 20 cut down and sold equity positions in Medicinova Inc so the sentiment improved. These funds own 8.63 million shares, that’s down from 8.79 million shares in 2018Q2. Funds holding Medicinova Inc in top 10 changed to 0 from 0 for the same number . 10 Investors Sold All; 10 Reduced Holdings; 19 increased holdings while 4 institutional investors bought holdings.

Largest Medicinova Inc Shareholders

As of Q3 2018 Wexford Capital Lp has 0.1% invested in Medicinova Inc. As of Q3 2018, 132,710 shares of Medicinova Inc are owned by Bridgeway Capital Management Inc. In addition, Alps Advisors Inc reported 74,109 shares in Medicinova Inc equivalent to 0.01% of its portfolio. The New York-based fund Alliancebernstein L.P. have invested about 0% of the fund’s stock portfolio in Medicinova Inc. The New York-based fund American International Group Inc looks positive on Medicinova Inc, having 26,444 shares.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.The firm is worth $396.20 million. The companyÂ’s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence.Currently it has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

The stock decreased 2.47% or $0.24 during the last trading session, hitting $9.46.MediciNova, Inc. has volume of 33,649 shares. Since January 14, 2018 MNOV has risen 28.16% and is uptrending. The stock outperformed the S&P500 by 28.16%.

Earnings report for MediciNova, Inc. (NASDAQ:MNOV) is awaited on February, 12., RTT reports.

Bank Of Montreal Can has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Manufacturers Life Company The invested in 27,325 shs. Fincl Bank Of New York Mellon holds 0% or 152,734 shs in its capital. Voya Invest Management Llc owns 15,925 shs or 0% of their US capital. Invesco has 0% invested in MediciNova, Inc. (NASDAQ:MNOV) for 10,583 shs. California State Teachers Retirement Systems holds 0% of its capital in MediciNova, Inc. (NASDAQ:MNOV) for 60,313 shs. California Public Employees Retirement accumulated 56,926 shs. Schwab Charles Investment Mgmt reported 86,235 shs stake. New York-based State Common Retirement Fund has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). 125,000 were accumulated by Wexford Cap Lp. Ameritas Investment Partners has 3,274 shs for 0% of their capital. Commercial Bank Of America Corporation De reported 0% in MediciNova, Inc. (NASDAQ:MNOV). Metropolitan Life Ins Co stated it has 2,752 shs or 0% of all its holdings. 658,185 are owned by State Street. Northern reported 0% stake.

For more MediciNova, Inc. (NASDAQ:MNOV) news released briefly go to: Globenewswire.com, Bioworld.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial – GlobeNewswire” released on July 29, 2018, “Medicinova shares climb on positive ALS trial analyses – BioWorld Online” on July 10, 2018, “National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova’s MN-166 (ibudilast) in Alcohol Use Disorder – GlobeNewswire” with a publish date: August 20, 2018, “MediciNova’s MN-166: Good Trial, But What About Generic Riluzole? – Seeking Alpha” and the last “MediciNova’s ibudilast shows encouraging action in ALS study; shares up 17% premarket – Seeking Alpha” with publication date: April 27, 2018.

MediciNova, Inc. (NASDAQ:MNOV) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.